IDEXX Laboratories expands test offerings for cancer diagnosis
Sundry Photography/iStock Editorial via Getty Images


IDEXX Laboratories (NASDAQ:IDXX)
announced the expansion of its reference laboratory menu of tests and services to help veterinarians diagnosing and treating cancer.
The extended menu, which will be available later this month to customers of IDEXX Reference Laboratories in the U.S. and Canada includes:

A liquid biopsy test that utilizes next-generation DNA sequencing technology to aid in diagnosing the most common canine cancers: lymphoma, hemangiosarcoma, and osteosarcoma.
A diagnostic panel for biopsy tissues that is used to identify genetic mutations in canines, assisting in therapy selection and personalized treatment options.
Newly designed diagnostic profiles to support cancer therapy management and monitoring.